BDTX Stock Risk & Deep Value Analysis

Black Diamond Therapeutics, Inc.

DVR Score

5.8

out of 10

Proceed with Caution

The Bottom Line on BDTX

We analyzed Black Diamond Therapeutics, Inc. using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran BDTX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Sep 25, 2025•Run Fresh Analysis →

📈BDTX Performance Overview3yr weekly

📊

Unlock BDTX Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

BDTX Deep Value Analysis

BDTX exhibits high-potential precision oncology vision, targeting significant unmet needs with a proprietary MAP platform and clear clinical catalysts. However, a major red flag is the short cash runway (~12 months), significantly increasing future dilution risk for current shareholders. While scientific potential for 10x exists, the financial trajectory creates a narrow window for success, requiring imminent, overwhelmingly positive clinical data to avoid being a 'dud' for existing investors through excessive dilution before major value inflection.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

🔔

Never miss a move on BDTX

Create a free account to set price alerts and get notified on Telegram when BDTX hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Black Diamond Therapeutics, Inc. (BDTX)?

As of September 25, 2025, Black Diamond Therapeutics, Inc. has a DVR Score of 5.8 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

How often is the BDTX DVR analysis updated?

Our AI-powered analysis of Black Diamond Therapeutics, Inc. is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on September 25, 2025.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.